Honokiol rescues progranulin deficiency in pathogen-induced and genetically driven neurodegeneration: Bridging veterinary models with therapeutic development

Zezhao Cao; Wenqi He; Ruijie Hu; Yuzhu Chen; Jun Xue; Feng Gao; Yungang Lan

doi:10.1016/j.vetmic.2025.110616

Honokiol rescues progranulin deficiency in pathogen-induced and genetically driven neurodegeneration: Bridging veterinary models with therapeutic development

Vet Microbiol. 2025 Jun 23:307:110616. doi: 10.1016/j.vetmic.2025.110616. Online ahead of print.

Authors

Zezhao Cao¹, Wenqi He¹, Ruijie Hu¹, Yuzhu Chen¹, Jun Xue¹, Feng Gao¹, Yungang Lan²

Affiliations

¹ State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun 130062, China.
² State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun 130062, China. Electronic address: lanyungang@jlu.edu.cn.

PMID: 40570712
DOI: 10.1016/j.vetmic.2025.110616

Abstract

Progranulin (PGRN), a crucial regulator of lysosomal function, is deficient in several neurodegenerative disorders. Restoring PGRN levels with small molecules presents a promising therapeutic strategy for these conditions. Honokiol (HNK), a polyphenolic compound known for its neuroprotective effects, has demonstrated potential in various neurodegenerative diseases (ND), though its precise mechanisms remain unclear. This study explores HNK's ability to upregulate PGRN expression in nerve cells and central nervous system tissues. Our results show that HNK enhances PGRN expression and lysosomal targeting in nerve cells, rescues PGRN deficiency in PHEV-infected models both in vitro and in vivo, and significantly increases brain PGRN levels in GRN haploinsufficient mice following oral administration. Collectively, these findings establish HNK's multimodal action as a promising therapeutic intervention for neurodegenerative conditions spanning both infectious (PHEV-mediated) and genetic (GRN-linked) etiologies of PGRN deficiency.

Keywords: GRN haploinsufficient model; HNK; ND; PGRN; PHEV-infected model.